Compare MasTec Inc (MTZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Novo Nordisk A/S — how do they compare? MasTec Inc trades at $214.25 (market cap $17.40B), while Novo Nordisk A/S trades at $38.39 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9.5× MasTec Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Novo Nordisk A/S for 116 Days on average.
| MTZ | NVO | |
|---|---|---|
Market Cap | $17.40B | $165.31B |
Volume | 1,415,821 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $437.51 | $63.98 |
52-Week Low | $190.08 | $35.29 |
Typical Hold Time | 23 Days | 116 Days |
Enterprise Value | $20.32B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.
The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
